Stories from people navigating cardiovascular disease — diagnosis, treatment, caregiving, and the ordinary days in between.
5 stories
Cardiology
A randomized-trial review favors SGLT2 inhibitors for heart failure hospitalization, while mortality differences from GLP-1 receptor agonists remain less certain.
Dr. Abu Bakar · October 11, 2026 · 6 min
Cardiology
A meta-analysis of 10 randomized datasets and 37,923 participants found distinct cardiorenal outcome patterns across SGLT2 inhibitors, finerenone and semaglutide, arguing against treating them as interchangeable.
Rayan Salih · 7 min read
Cardiology
Across 35 randomized trials, high-dose omega-3 treatment was associated with higher atrial fibrillation risk. The absolute increase was modest but relevant for cardiovascular patients.
Rayan Salih · 6 min read
Cardiology
A 2026 meta-analysis estimated 32% lower odds of major cardiovascular events with semaglutide. The result supports cardiovascular benefit discussions but requires context on heterogeneity, absolute risk and indication.
Dr. Abu Bakar · 6 min read
Cardiology
TRACK found no cardiovascular benefit and more major bleeding when low-dose rivaroxaban was added in stage 4–5 CKD or dialysis-dependent kidney failure.
Rayan Salih · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.